Mounjaro Weight Loss Tracker UK: What to Log Each Week

A Mounjaro weight loss tracker in the UK should do more than record the number on the scales. It should help you connect weekly weight change with your dose, jab date, side effects, appetite, food routine, activity, and the questions you want to raise with your GP, specialist service, chemist, or prescribing pharmacy.

The UK context matters. The MHRA authorisation is UK-wide, while NHS access routes depend on where you live and local commissioning. NICE has recommended tirzepatide for some adults with overweight or obesity, and NHS England access is being phased. Many people investigating Mounjaro are also comparing NHS assessment, specialist weight management services, and private pharmacy routes. A clear tracker helps you have a more useful conversation whichever route applies to you.

Quick answer: the best Mounjaro tracker for UK users is a weekly log that records weight, dose, jab date, injection site, symptoms, appetite, waist measurement, activity, and review notes. GlucoPal is built around that routine, with simple check-ins that keep your Mounjaro history in one place.

The best UK Mounjaro tracker records dose, weight, symptoms, and review notes

A useful Mounjaro tracker starts with the facts your prescriber or pharmacist may ask about: when you took each jab, what dose you used, what your weight did over time, and whether side effects changed after a dose increase.

Mounjaro is a once-weekly tirzepatide injection. UK product information lists the starting dose as 2.5 mg once weekly, followed by 5 mg once weekly after 4 weeks, with further increases in 2.5 mg steps after at least 4 weeks on the current dose if needed. That means a tracker should not treat every week as identical. Week 2 on 2.5 mg is different from week 2 after moving up to 7.5 mg.

Use your tracker as a simple timeline, not a verdict. Day-to-day water weight, digestion, menstrual cycle timing, salt intake, travel, illness, and changes in training can all move the scale. Weekly tracking gives you a calmer signal.

GlucoPal feature moment: log your dose, jab date, injection site, weight, and notes in the same weekly check-in, so you are not piecing together a Mounjaro history from receipts, calendar entries, and memory.

UK access rules make tracking more important than a simple scales app

In the UK, "am I losing weight?" is only one part of the Mounjaro question. You may also need to understand whether you meet NHS criteria, whether your access route is specialist or primary care, and what information your prescriber will review before dose changes or continuation.

The MHRA authorised Mounjaro for weight management in adults with obesity, or adults who are overweight and have at least one weight-related health problem. NICE guidance for NHS use in England is narrower for cost-effectiveness and implementation reasons: tirzepatide is recommended for adults with an initial BMI of at least 35 kg/m2 and at least one weight-related comorbidity, with lower BMI thresholds usually used for some ethnic backgrounds.

NHS England is phasing access in primary care. As of 27 April 2026, NHS England says initial primary care access is for people with the highest clinical need: obesity, 4 listed weight-related health problems, and a BMI of 40 or more, adjusted for ethnicity. NICE says eligibility is expected to broaden in phases, including from around June 2026 for people with 4 listed weight-related health conditions and a BMI between 35 and 39.9 kg/m2.

That makes tracking practical. If you are investigating Mounjaro through a GP, specialist service, or registered pharmacy, bring a record that separates:

• your starting weight and BMI context
• your current dose and how long you have been on it
• your weight trend, not just your latest weigh-in
• side effects that affect eating, hydration, work, sleep, or daily life
• current medicines and health conditions your prescriber already needs to know about

A tracker cannot decide eligibility or prescribe treatment. It can make the assessment conversation less vague.

Track weekly progress against dose changes, not daily scale noise

Mounjaro progress is usually easier to understand when you compare like with like: starting weight, dose stage, and weeks on treatment. A daily weigh-in can be useful for some people, but a weekly trend is usually a better fit for a once-weekly jab.

NICE advises clinicians to discuss the weight loss needed to show tirzepatide is working. It also says that if less than 5% of initial weight has been lost after 6 months on the highest tolerated dose, the benefits and risks of continuing treatment should be reviewed for that person.

That does not mean you should judge your results after one month. The 2.5 mg starting dose is part of the titration process, and side effects can be more common during escalation. What matters is whether your record shows a pattern over enough time and at the dose your prescriber considers relevant.

For a clean Mounjaro weight loss tracker, keep these weekly fields consistent:

• Weight: weigh under similar conditions, such as the same morning each week.
• Dose week: write "5 mg week 1" rather than only "Mounjaro".
• Side effects: include nausea, vomiting, diarrhoea, constipation, reflux, fatigue, or injection-site reactions if they occur.
• Hydration and eating notes: especially if sickness, diarrhoea, or low intake affected the week.
• Activity: record a realistic marker, such as steps, gym sessions, walking, or physiotherapy-led activity.

GlucoPal feature moment: use the weight trend and dose timeline together. That makes it easier to see whether a slower week happened during a dose change, a difficult side-effect week, a holiday, or an ordinary fluctuation.

A good tracker prepares you for GP, pharmacy, and specialist reviews

A UK Mounjaro tracker should help you talk to healthcare professionals without turning every appointment into a memory test. The most useful record is concise: what happened, when it happened, and whether it affected your ability to eat, drink, work, sleep, or take other medicines.

NICE's prescribing resource highlights follow-up and monitoring during titration, including discussion of injection difficulties and side effects. It also warns that gastrointestinal side effects such as nausea, vomiting, and diarrhoea are common but can sometimes lead to serious dehydration. The UK SmPC advises that injection sites should be rotated with each dose and notes that Mounjaro is injected under the skin of the abdomen, thigh, or the back of the upper arm when another person gives the injection.

Your tracker is especially useful before these conversations:

• Dose increase check: show whether side effects settled before moving up.
• Side-effect discussion: record timing, severity, hydration, and what helped.
• Missed-dose concern: show the exact jab date and your usual weekly schedule.
• NHS or private review: bring starting weight, current weight, dose history, and lifestyle support notes.
• Other medicines: list diabetes medicines, contraception, HRT, or other treatments your clinician has asked you to monitor.

Seek medical help urgently for symptoms your clinician has warned you about, such as sudden severe abdominal pain, signs of serious dehydration, a serious allergic reaction, or any worrying symptom after starting or increasing Mounjaro. A tracker is not a substitute for urgent advice.

GlucoPal feature moment: keep side effects next to your dose history, so "felt awful" becomes a clearer note such as "7.5 mg week 1, vomiting day 2, poor fluids, improved day 4".

GlucoPal is best used as a weekly Mounjaro habit, not a medical decision-maker

GlucoPal can help you keep your Mounjaro routine visible, but it should not decide whether Mounjaro is right for you, whether you should increase dose, or whether you should continue treatment. Those decisions belong with your prescriber, GP, pharmacist, nurse, or specialist weight management service.

Use GlucoPal for the parts of the journey that are easy to lose track of:

• the date of each jab
• dose stage and dose changes
• injection site rotation
• weight and waist trend
• side effects and appetite notes
• questions to ask at your next review

This is particularly helpful if you are comparing support options. A general weight loss app may show a chart. A Mounjaro-specific tracker should help you understand the treatment timeline: titration, tolerability, weekly jab routine, diet and activity support, and review points.

If you are already using Mounjaro or preparing for a prescriber conversation, you can find GlucoPal on the App Store and use it as a simple weekly companion for your notes.

FAQ

What should I put in a Mounjaro weight loss tracker?

Track your starting weight, current weight, dose, jab date, injection site, side effects, appetite, waist measurement, activity, and review questions. The most useful tracker shows the timeline, not just the latest number on the scales.

Is Mounjaro available on the NHS in the UK?

Mounjaro is recommended by NICE for some adults with overweight or obesity, but NHS access depends on where you live. In England, access is being phased and, as of 27 April 2026, initial primary care access is focused on people with the highest clinical need. Check your local NHS pathway or speak to your GP or specialist service for current eligibility.

How often should I weigh myself on Mounjaro?

Many people use a weekly weigh-in because Mounjaro is taken once weekly and daily changes can be noisy. If you weigh more often, still judge progress by the trend over several weeks rather than one isolated day.

Should I track side effects as well as weight?

Yes. Side effects can affect hydration, eating, work, sleep, and whether a dose increase feels manageable. Record what happened, when it started, how severe it was, and whether it settled.

Can a tracker tell me when to increase my Mounjaro dose?

No. A tracker can show your dose history, weight trend, and side effects, but dose decisions should be made with your prescriber using your medical history and current symptoms.

Sources

1. NICE TA1026: Tirzepatide for managing overweight and obesity - UK recommendations, BMI thresholds, phased implementation notes, and the 5% review point
2. NHS England: Weight management injections - current England rollout details, primary care phasing, wraparound care, and patient-facing cautions
3. MHRA: Mounjaro authorised for weight management and weight loss - UK authorisation, indicated BMI groups, weekly dosing overview, and approved injection areas
4. Mounjaro KwikPen Summary of Product Characteristics on eMC - UK product information, dose titration, four-dose KwikPen details, injection site rotation, side effects, and Yellow Card reporting information
5. NICE prescribing resource: prescribing, reviewing and stopping tirzepatide - practical monitoring, follow-up, side-effect counselling, and review guidance